Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2
- 24 October 2006
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 28 (1) , 13-18
- https://doi.org/10.1002/bdd.527
Abstract
The bile salt export pump (BSEP/Bsep/ABCB11) and multidrug resistance‐associated protein 2 (MRP2/Mrp2/ABCC2) are involved in bile acid‐dependent and ‐independent bile secretion, respectively. It has been reported that bosentan, an endothelin receptor antagonist, inhibits Bsep, which may lead to cholestatic liver injury due to the intracellular accumulation of bile salts, while increasing bile salt‐independent bile flow. Thus, in this study, the effects of bosentan on BSEP/Bsep and MRP2/Mrp2 were evaluated using membrane vesicles derived from Spodoptera frugiperda (Sf) 9 cells, which express these transporters. The adenosine 5′‐triphosphate (ATP)‐dependent uptake of 3H‐taurocholic acid into membrane vesicles for BSEP/Bsep was inhibited by bosentan, and its IC50 values were 76.8 and 101 µM for BSEP and Bsep, respectively. In contrast, bosentan stimulated the MRP2/Mrp2‐mediated ATP‐dependent vesicular transport of 3H‐estradiol 17β‐glucuronide by shifting the sigmoidal dependence of transport rate on substrate concentration to a more hyperbolic one. Collectively, these results suggest that bosentan inhibits BSEP in humans with a similar potency to rats, and that increased bile salt‐independent flow in rats by bosentan is at least partly attributable to the activation of Mrp2. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 15 references indexed in Scilit:
- Mrp2/Abcc2 transport activity is stimulated by protein kinase Cα in a baculo virus co-expression systemLife Sciences, 2005
- Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3The Journal of Pharmacology and Experimental Therapeutics, 2004
- Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the RatThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor AntagonistClinical Pharmacokinetics, 2004
- Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)Journal of Biological Chemistry, 2003
- The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactionsClinical Pharmacology & Therapeutics, 2001
- Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic AnionsMolecular Pharmacology, 2000
- A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasisNature Genetics, 1998
- Intrahepatic cholestasis of pregnancy: A French prospective studyHepatology, 1997
- Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in manDigestive Diseases and Sciences, 1992